Evogenix to licence new antibody technology

Published: 26-Jul-2005

Australian antibody drug company Evogenix has developed a technology designed to identify and refine new antibody drugs. The company hopes to have its first product, which targets bone loss in osteoporosis patients, ready to license to a pharmaceutical company next year.


Australian antibody drug company Evogenix has developed a technology designed to identify and refine new antibody drugs. The company hopes to have its first product, which targets bone loss in osteoporosis patients, ready to license to a pharmaceutical company next year.

Ceo Dr Merilyn Sleigh said the company had a different business model compared with many Australian biotech companies because of its focus on generating short-term revenue through licensing its technology to third-party drug developers.

He said the company aimed to start one new antibody programme a year and maintain three products at any one time, using funds from its A$9m (€5.7m) initial public offer.

You may also like